Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17465376 | 0.81 | SLC6A3 (0.36) | ALOX15FDPSSLC6A3CYP1A2CYP2C9 | |
| SCHEMBL1143697 | 0.74 | PTGS1 (0.41) | ALOX15ALDH1A1TRPM8 | |
| SCHEMBL1143891 | 0.74 | ALOX15 (0.36) | ALOX15PTPN2PTPN1CDC25B | |
| SCHEMBL13736951 | 0.74 | FDPS (0.31) | FDPS | |
| SCHEMBL1143539 | 0.73 | FDPS (0.38) | ALOX15FDPSPTPN2PTPN1CDC25B | |
| SCHEMBL1143922 | 0.73 | ALOX15 (0.36) | ALOX15PTPN2PTPN1CDC25BSLC6A3 | |
| SCHEMBL1143641 | 0.73 | CYP1A2 (0.46) | ALOX15FDPSCYP1A2ALDH1A1 | |
| SCHEMBL1143784 | 0.71 | TAAR1 (0.37) | ALOX15PTPN2PTPN1CDC25BCYP1A2 | |
| SCHEMBL7554702 | 0.70 | ALOX15 (0.58) | ALOX15PTPN2PTPN1CDC25BCYP2C9 | |
| SCHEMBL1143532 | 0.70 | KCNQ2 (0.36) | ALOX15PTPN2PTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486435-B2 | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | claimed |
| US-20150297551-A1 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2015-10-22 | — | — | US | claimed |
| US-8952071-B2 | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | claimed |
| US-20110046219-A1 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS, INC | 2011-02-24 | — | — | US | claimed |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | BIOJIVA LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12156860-B2 | Disorders implicating PUFA oxidation | BIOJIVA LLC (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | BIOJIVA LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | BIOJIVA LLC | 2022-09-29 | — | — | US | disclosed |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | BIOJIVA LLC | 2022-05-05 | — | — | US | disclosed |
| US-11285125-B2 | Oxidative retinal diseases | RETROTOPE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | RETROTOPE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-8952071-B2 | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140147428-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RETROTOPE, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140050712-A1 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140044692-A1 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20110046219-A1 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS, INC | 2011-02-24 | — | — | US | disclosed |
| EP-2237664-A1 | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | Edison Pharmaceuticals, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009089224-A1 | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | ALOX15 9/4885FDPS 2118/4885PTPN2 4753/4885 |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | CPT1B, PSEN2, NLN | ALOX15 9/4885FDPS 2118/4885PTPN2 4753/4885 |
| US-12156860-B2 | Disorders implicating PUFA oxidation | GPX4, CPT1A, FABP1 | ALOX15 9/4885FDPS 578/4885PTPN2 1898/4885 |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | ALOX15 19/4885FDPS 1441/4885PTPN2 4111/4885 |
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | ALOX15 19/4885FDPS 1441/4885PTPN2 4111/4885 |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | ALOX15 9/4885FDPS 578/4885PTPN2 1898/4885 |
| US-20150297551-A1 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, ECHS1, NDUFS6 | ALOX15 232/4885FDPS 257/4885PTPN2 4345/4885 |
| US-11285125-B2 | Oxidative retinal diseases | ALDH1A2, TXNRD2, STARD3 | ALOX15 19/4885FDPS 1441/4885PTPN2 4111/4885 |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | CPT1B, PSEN2, NLN | ALOX15 9/4885FDPS 2118/4885PTPN2 4753/4885 |
| US-20140147428-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | ALOX15 9/4885FDPS 2118/4885PTPN2 4753/4885 |
| US-20140050712-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | ALOX15 9/4885FDPS 578/4885PTPN2 1898/4885 |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | ACADM, CPT1A, ALDH2 | ALOX15 43/4885FDPS 606/4885PTPN2 4793/4885 |
| US-20140044692-A1 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | NDUFAB1, PC, HADHB | ALOX15 504/4885FDPS 356/4885PTPN2 4527/4885 |
| US-20110046219-A1 | (HET)ARYL-P-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, ECHS1, NDUFS6 | ALOX15 232/4885FDPS 257/4885PTPN2 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.